About Us

Company Overview

BriSTAR Immunotech is a clinical-stage cell therapy company dedicated to the development and commercialization of innovative engineered T cell immunotherapy products for the treatment of cancer and viral infections.

BriSTAR Immunotech was founded in 2018 by internationally-renowned molecular immunologist, Dr. Lin Xin and his team at Tsinghua University.

Development history


Submitting a new IND

Preclinical data AACR released

Two solid tumor products entered early clinical stage


B+ round financing

Submitted the first IND

New CMC & QC facilities completed


B-round financing

Paper on STAR-T published

IIT date presented at EHA conference


A+round financing

Moved in Beijing R&D headquarter

IIT Data presented in ASH conference


A-round financing

Initiated STAR-T IIT


Company was founded (Dr. Lin Xin)

Angel round fiInancing

Pre-A round financing

Initiated TCR-T IIT